Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application for PRT12396, a Mutant-selective JAK2V617F Inhibitor
Metalsource Mining Intersects 1.1kg/t AgEq over 3.1m, Continues Identifying Widespread Polymetallic Mineralization While Expanding the Dip Length of the System Approximately 260m from Surface
